Interventional studies report beneficial effects of B1344, a long-acting polyethylene glycosylated (PEGylated) FGF21 analogue, on lowering hepatic fibrosis and protecting against the progression of NASH in rodents and nonhuman primates [120]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.